Multinational phase 2 trial of avutometinib with or without defactinib in recurrent low-grade serous ovarian cancer

The multinational phase 2 ENGOT-OV60/GOG-3052/RAMP 201 trial evaluated avutometinib with or without defactinib for recurrent low-grade serous ovarian cancer (LGSOC). The trial showed that the combination of avutometinib 3.2 mg two times per week plus defactinib 200 mg two times per day resulted in clinically meaningful responses, duration of response, and progression-free survival, particulary in the KRAS-mutant cohort. Adverse events were manageable, mainly with dose holds or reductions, allowing 90% of patients to stay on therapy. The authors conclude that the combination of avutometinib and defactinib is a potential standard of care for recurrent LGSOC.